ABSTRACT
Pharmacokinetics of ketoprofen nanosystem was studied in outbred rats after single endotracheal administration. Ketoprofen was analyzed in blood serum and tissues by HPLC with UV detection. After endotracheal administration of the nanosystem, ketoprofen rapidly appears in systemic blood flow and its concentration in blood serum reaches maximum after 15 min. The maximum drug concentration in tissues was observed near the site of introduction, namely, in lungs Ketoprofen showed moderate penetration in tissues with high vascularization, and weak penetration in tissues with moderate vascularization. After endotracheal administration of the nanosystem, only small amount of ketoprofen overcomes the blood brain barrier.
Subject(s)
Blood-Brain Barrier/metabolism , Drug Carriers , Ketoprofen , Nanostructures , Administration, Inhalation , Animals , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Drug Carriers/pharmacology , Ketoprofen/chemistry , Ketoprofen/pharmacokinetics , Ketoprofen/pharmacology , Male , Nanostructures/chemistry , Nanostructures/therapeutic use , RatsABSTRACT
A simple, specific and sensitive RP-HPLC method with UV detection for the determination of hopantenic acid in human blood plasma has been developed. The pharmacokinetics of drug pantocalcin upon single peroral administration was investigated on 18 healthy volunteers. The peak of hopantenic acid in blood plasma was achieved at 1.56 h and the elimination half life was 6.68 h. No hopantenic acid in blood plasma is found in 48 h.
Subject(s)
Nootropic Agents/administration & dosage , Nootropic Agents/pharmacokinetics , Pantothenic Acid/analogs & derivatives , gamma-Aminobutyric Acid/analogs & derivatives , Administration, Oral , Adult , Chromatography, High Pressure Liquid , Female , Half-Life , Humans , Male , Pantothenic Acid/administration & dosage , Pantothenic Acid/pharmacokinetics , gamma-Aminobutyric Acid/administration & dosage , gamma-Aminobutyric Acid/pharmacokineticsABSTRACT
Light-absorbing and antiradical properties of the new product on a basis of lutein and zeaxanthin for correction of eye diseases in model system of initiated oxidation of isopropylbenzene were investigated. It is shown, that the product is the effective light-absorbing agent and inhibitor of free-radical oxidation in vitro. In experiments on animals (rat) the pharmacokinetics of the product was investigated at single oral administration. A simple, specific and sensitive RP-HPLC method for the determination of lutein in rat plasma was developed, which was applied to pharmacokinetic investigation in rats after oral administration of lutein at dose 20 mg/kg. It was established, that the peak plasma levels was achieved to 2 hour and the mean elimination half life was 2,4 hours.
